Friday, November 7: Shares of Bliss GVS Pharma Ltd declined sharply by 15.8% to Rs 127.94 in early trade after the company reported a 20% year-on-year (YoY) fall in EBITDA for the quarter ended September 2025 (Q2 FY26). The company’s EBITDA margin also contracted to 13%, compared with 18.3% in the same period last year, signalling rising cost pressures.
The stock opened weak following the company’s Q2 results announcement, where revenue from operations rose 4.8% YoY to Rs 245.86 crore, but profitability took a hit due to elevated raw material and employee expenses.
Net profit for the quarter rose marginally by 2.5% YoY to Rs 25.69 crore, compared with Rs 25.08 crore in Q2 FY25. However, the sharp decline in operational performance weighed heavily on investor sentiment.
At 9:33 a.m. IST, Bliss GVS Pharma was trading at Rs 127.94, down Rs 24.04 from the previous close of Rs 151.98 on the National Stock Exchange (NSE). The stock hit an intraday low of Rs 125, with a market capitalization of Rs 1,393 crore.
Analysts attribute the steep fall to weaker-than-expected operating performance and margin compression, despite steady revenue growth and stable net profits.
Disclaimer:
The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
